HK Movers | Biopharma Company Vigonvita Soars 134% in Hong Kong's Grey Market Trading

Tiger Newspress

11/05

Biopharmaceutical company Vigonvita Life Sciences soared 134% in Hong Kong’s grey market trading.

Vigonvita Life Sciences develops biomedicine. The Company produces and sells innovative small molecule drugs, anti-viral drugs, and other products. Vigonvita Life Sciences markets its products primarily throughout China with limited overseas.

Vigonvita reportedly oversubscribed by 4,974 times through margin financing, and priced near the upper limit at HKD33.37 per share.

With a target issuance of 17.598 million shares, it is expected to raise HKD587 million. This round of IPO does not involve a clawback regime. The stock is anticipated to officially list tomorrow (6th).

Retail investors shared images on social media, indicating that even after splashing HKD30.214 million for maximum subscription of 879,800 shares, they still failed to secure a lot of 200 shares, marking the 9th instance under the new clawback regime.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1174827669"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174827669\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174827669?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 16:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174827669","market":"hk","top_or_hot":-1,"title":"HK Movers | Biopharma Company Vigonvita Soars 134% in Hong Kong's Grey Market Trading","media":"Tiger Newspress","content":"<html><head></head><body><p>Biopharmaceutical company Vigonvita Life Sciences soared 134% in Hong Kong’s grey market trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/3852f8d6a146598a14c2f3937d41429d\" title=\"\" tg-width=\"960\" tg-height=\"612\"/></p><p>Vigonvita Life Sciences develops biomedicine. The Company produces and sells innovative small molecule drugs, anti-viral drugs, and other products. Vigonvita Life Sciences markets its products primarily throughout China with limited overseas.</p><p>Vigonvita reportedly oversubscribed by 4,974 times through margin financing, and priced near the upper limit at HKD33.37 per share.<br/><br/>With a target issuance of 17.598 million shares, it is expected to raise HKD587 million. This round of IPO does not involve a clawback regime. The stock is anticipated to officially list tomorrow (6th).</p><p>Retail investors shared images on social media, indicating that even after splashing HKD30.214 million for maximum subscription of 879,800 shares, they still failed to secure a lot of 200 shares, marking the 9th instance under the new clawback regime.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Movers | Biopharma Company Vigonvita Soars 134% in Hong Kong's Grey Market Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Movers | Biopharma Company Vigonvita Soars 134% in Hong Kong's Grey Market Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2025-11-05 16:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Biopharmaceutical company Vigonvita Life Sciences soared 134% in Hong Kong’s grey market trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/3852f8d6a146598a14c2f3937d41429d\" title=\"\" tg-width=\"960\" tg-height=\"612\"/></p><p>Vigonvita Life Sciences develops biomedicine. The Company produces and sells innovative small molecule drugs, anti-viral drugs, and other products. Vigonvita Life Sciences markets its products primarily throughout China with limited overseas.</p><p>Vigonvita reportedly oversubscribed by 4,974 times through margin financing, and priced near the upper limit at HKD33.37 per share.<br/><br/>With a target issuance of 17.598 million shares, it is expected to raise HKD587 million. This round of IPO does not involve a clawback regime. The stock is anticipated to officially list tomorrow (6th).</p><p>Retail investors shared images on social media, indicating that even after splashing HKD30.214 million for maximum subscription of 879,800 shares, they still failed to secure a lot of 200 shares, marking the 9th instance under the new clawback regime.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02630","symbol_name":"旺山旺水-B","start_time":0,"source_url":"","article_id":"1174827669","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174827669","pubTimestamp":1762330797,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Vigonvita stock soared 134% in Hong Kong’s grey market trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02630":"旺山旺水-B"},"translate_title":"HK Movers|生物制药公司Vigonvita在香港灰色市场交易中飙升134%","themeId":"c9a0abbe225b61c5dcb2243713c8d063","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02630":2},"content_text":"Biopharmaceutical company Vigonvita Life Sciences soared 134% in Hong Kong’s grey market trading.Vigonvita Life Sciences develops biomedicine. The Company produces and sells innovative small molecule drugs, anti-viral drugs, and other products. Vigonvita Life Sciences markets its products primarily throughout China with limited overseas.Vigonvita reportedly oversubscribed by 4,974 times through margin financing, and priced near the upper limit at HKD33.37 per share.With a target issuance of 17.598 million shares, it is expected to raise HKD587 million. This round of IPO does not involve a clawback regime. The stock is anticipated to officially list tomorrow (6th).Retail investors shared images on social media, indicating that even after splashing HKD30.214 million for maximum subscription of 879,800 shares, they still failed to secure a lot of 200 shares, marking the 9th instance under the new clawback regime.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}